Stockreport

Galecto to Highlight GB3226 Program at ASH 2025

Galecto, Inc.  (GLTO) 
PDF Two Presentations at ASH 2025 to highlight preclinical data and clinical development plans for GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of acu [Read more]